Concord Drugs Ltd vs Zydus Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 85.04 as of 05 May 15:30 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 8 on March 2022 to 21.1 on March 2021 . This represents a CAGR of 21.41% over 5 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 35697 crore on March 2022 to ₹ 45131 crore on March 2021 . This represents a CAGR of 4.80% over 5 years The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The revenue of Zydus Lifesciences Ltd for the Dec '25 is ₹ 6975 crore as compare to the Sep '25 revenue of ₹ 6232 crore. This represent the growth of 11.93% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The ebitda of Zydus Lifesciences Ltd for the Dec '25 is ₹ 1842 crore as compare to the Sep '25 ebitda of ₹ 2090 crore. This represent the decline of -11.85% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The net profit of Zydus Lifesciences Ltd changed from ₹ 1463 crore to ₹ 965.1 crore over 7 quarters. This represents a CAGR of -21.18% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 24.28 % on March 2021 to 19.16 % on March 2025 . This represents a CAGR of -4.63% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited, initially known as Cadila Healthcare Limited was incorporated in May, 1995, which changed to Zydus Lifesciences Limited on February 24, 2022.
The Company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. The Company's operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products.

FAQs for the comparison of Concord Drugs Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Zydus Lifesciences Ltd?

Market cap of Concord Drugs Ltd is 112 Cr while Market cap of Zydus Lifesciences Ltd is 91,753 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Zydus Lifesciences Ltd?

The stock performance of Concord Drugs Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Zydus Lifesciences Ltd?

As of May 5, 2026, the Concord Drugs Ltd stock price is INR ₹85.04. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹911.85.

How do dividend payouts of Concord Drugs Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.